12 February 2019

Gernandt & Danielsson advises Moberg Pharma in connection with the divestment of its OTC-business for USD 155 million and the funding of its development programs

Gernandt & Danielsson advises the pharmaceutical company Moberg Pharma AB (publ) ("Moberg Pharma") in connection with the divestment of its Global Consumer Health Business, comprising direct and distributor sales of over-the-counter brands, to RoundTable Healthcare Partners and Signet Healthcare Partners for a cash consideration of USD 155 million. In addition, Moberg Pharma obtains funding for its pipeline programs with a total amount of USD 5 million, including a share issue and a loan with pertaining warrants.

Moberg Pharma will use the cash consideration to redeem its bonds and make a distribution to its shareholders. The transaction is among other things conditional upon approval at a general meeting in Moberg Pharma and is expected to close by the end of March 2019.

Moberg Pharma develops and commercialises over-the-counter pharmaceuticals and has since its listing on Nasdaq Stockholm in 2010 assembled a product portfolio composed of well established brands. In addition, Moberg Pharma has a pipeline of late stage drug candidates.

Gernandt & Danielsson advises Moberg Pharma with a team consisting of Partners Mikael Borg and Fredrik Palm, Counsel Adrian Della Morte Pålstam and Associates Katarina Odelberg and Alexander Grägg. Hansen Law has also advised Moberg Pharma on the transaction.